Canagliflozin and cardiovascular and renal events in type 2 diabetes

New England Journal of Medicine

Volumn 377, Issue 7, 2017, Pages 644-657

  Neal, Bruce ^a,b,c   Perkovic, Vlado ^a,b   Mahaffey, Kenneth W ^e   De Zeeuw, Dick ^f   Fulcher, Greg ^b   Erondu, Ngozi ^g   Shaw, Wayne ^g   Law, Gordon ^g   Desai, Mehul ^g   Matthews, David R ^d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; PLACEBO; ANTIDIABETIC AGENT;

ADULT; ALBUMINURIA; AMPUTATION; ARTICLE; CARDIOVASCULAR DISEASE; CAUSAL ATTRIBUTION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FRACTURE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; METATARSAL BONE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEX RATIO; SINGLE BLIND PROCEDURE; TOE; AGED; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; DRUG EFFECTS; FOOT; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; KIDNEY DISEASES; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; STATISTICS AND NUMERICAL DATA; SURGERY;

AGED; ALBUMINURIA; AMPUTATION; CANAGLIFLOZIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; FOOT; GLOMERULAR FILTRATION RATE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; MALE; MIDDLE AGED;

EID: 85023777061     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1611925     Document Type: Article

References (24)

1. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015;385:1975-82.
2. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21.
3. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159:262-74.
4. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-97.
5. Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016;4:411-9.
6. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
7. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34.
8. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) — a randomized placebo-controlled trial. Am Heart J 2013;166(2):217-223.e11.
9. Neal B, Perkovic V, Matthews DR, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab 2017;19:387-93.
10. Neal B, Perkovic V, Mahaffey KW, et al. Optimizing the analysis strategy for the CANVAS Program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 2017 February 28 (Epub ahead of print).
11. Cox DR. Regression models and life tables (with discussion). J R Stat Soc [Ser B] 1972;34:187-220.
12. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer, 2000.
13. Rabelink TJ, de Zeeuw D. The glycocalyx — linking albuminuria with renal and cardiovascular disease. Nat Rev Nephrol 2015;11:667-76.
14. Ballermann BJ, Brenner BM. Atrial natriuretic peptide and the kidney. Am J Kidney Dis 1987;10:Suppl 1:7-12.
15. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015; 313:603-15.
16. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 2013;185:949-57.
17. Ortola FV, Ballermann BJ, Anderson S, Mendez RE, Brenner BM. Elevated plasma atrial natriuretic peptide levels in diabetic rats: potential mediator of hyperfiltration. J Clin Invest 1987;80:670-4.
18. Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013;83:517-23.
19. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
20. Vallianou NG, Geladari E, Kazazis CE. SGLT-2 inhibitors: their pleiotropic properties. Diabetes Metab Syndr 2016 December 9 (Epub ahead of print).
21. Wong MG, Perkovic V, Chalmers J, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 2016;39:694-700.
22. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435-43.
23. Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017;5:431-7.
24. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016;101:157-66.